New Influenza Vaccine Fails to Meet Efficacy Goal
The candidate will now be evaluated as part of a combination strategy for future flu seasons.
Updated on Oct. 15, 2026 in Diseases — General
Live Poll
Do you feel confident that new vaccine technologies will improve your protection against seasonal influenza?
Osivax recently reported that its OVX836 influenza vaccine candidate failed to meet its primary efficacy goal in a large Phase 2b clinical trial. The company now plans to pivot toward developing combination vaccines that pair this candidate with traditional seasonal shots.
Why it matters
While the standalone vaccine fell short of its efficacy target, the study suggests that combining different technologies may offer more robust protection against influenza. This shift represents a new approach to improving vaccination coverage against evolving flu strains.
A Phase 2b trial involving 2,850 healthy adults evaluated the efficacy of the OVX836 vaccine compared to a placebo. The vaccine achieved a point estimate efficacy of 24%, missing the 50% target.
The players
Osivax
A biotechnology company based in France and Belgium focused on developing nanoparticle-based vaccines.
GC Biopharma
A pharmaceutical partner collaborating with Osivax on vaccine development.
The details
The OVX836 vaccine is designed to target the influenza A nucleoprotein antigen, a core part of the virus that is more stable than surface proteins. The study tested a single 480 microgram intramuscular dose using the company's oligoDOM technology, which creates nanoparticle-based vaccines. Although the candidate showed a favorable safety profile, it did not provide sufficient standalone protection against the virus.
Timeline
October 15, 2026: Osivax announced results from the Phase 2b clinical trial.
Q4 2027: The company expects to initiate its first Phase 1/2 study for a combination vaccine.
Health Landscape
Most seasonal flu vaccines focus on surface proteins that mutate rapidly, requiring frequent updates to formulations. Targeting the influenza A nucleoprotein antigen is an attempt to create more durable, cross-reactive protection.
This development does not change your current vaccination schedule or choice of available flu shots. The efficacy of future combination vaccines is still under study, so continue to follow existing annual influenza vaccination guidance provided by your physician.
The takeaway
While this specific candidate did not reach its efficacy goals, the move toward combination vaccines highlights a shift in flu prevention research. Always consult with your primary care physician to stay updated on the most effective influenza protection strategies available each season.
What happens next
Osivax plans to start a Phase 1/2 combination vaccine study in the fourth quarter of 2027.
Further reading
Learn more about the latest innovations in Diseases — General.
More information
For more information on the research, visit the clinical trial study information.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you feel confident that new vaccine technologies will improve your protection against seasonal influenza?
